In HCC, the CD133+ subtype of CSC cells has been characterized as being involved in the activation of Akt molecular pathway and the b-lymphoma-2 (Bcl-2) cell survival pathway to resist cytotoxicity from chemotherapy drugs such as sorafenib (Ma et al., 2008). Here, PROM1 is linked to hepatocellular carcinoma.